Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative Allo-SCT for Hematologic Malignancies
NCT00053989Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jan 2002
- Primary completion
- Jul 2018
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, fludarabine in hematologic malignancy, aplastic anemia, sponsored by Roswell Park Comprehensive Cancer Center. Started Jan 2002; status: completed.
02
Drugs
cyclophosphamidefludarabine
03
Conditions
hematologic malignancyaplastic anemia
Beyond the preview
Go deeper on NCT00053989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053989.